Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy (ASTRAL-4LV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04463641
Recruitment Status : Not yet recruiting
First Posted : July 9, 2020
Last Update Posted : July 9, 2020
Sponsor:
Information provided by (Responsible Party):
MicroPort CRM

Brief Summary:
The primary objective of this study is to assess the chronic safety and performance of the Axone left ventricular (LV) micro-lead.

Condition or disease Intervention/treatment Phase
Heart Failure Cardiac Resynchronization Therapy Device: Implantation of the Axone 4LV Lead Not Applicable

Detailed Description:

This is a interventional, pivotal, prospective, single arm, open label, multicenter, international trial.

The device under investigation is the Axone system, consisting of:

  • Axone 4LV: an ultrathin, lumenless, quadripolar, IS4-compatible lead designed for left ventricular pacing for cardiac resynchronization therapy (CRT).
  • Axone µGuide: a dedicated, permanently implantable micro catheter designed for implantation of the Axone 4LV lead.

The primary endpoint data will be used to support CE marking of the Axone system.

The primary endpoints will be evaluated at 6 months post-implantation. Subjects will be followed-up at 6 weeks, 3 months, 6 months, 12 months post-implantation, then yearly until 4 years post-implantation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : December 2025

Arm Intervention/treatment
Experimental: Axone 4LV Lead
Subjects implanted with the Axone 4LV Lead
Device: Implantation of the Axone 4LV Lead
Implantation of the Axone 4LV Lead




Primary Outcome Measures :
  1. Safety co-primary endpoint, defined as Axone system related complication free rate at 6 months post implant [ Time Frame: 6 months ]
    A complication is defined as any Serious Adverse Device Effect (SADE) resulting in death or requiring invasive intervention. Safety co-primary endpoint assessment will be based on independent event adjudication by a Clinical Event Committee (CEC).

  2. Performance co-primary endpoint, defined as LV pacing success rate at 6 months post implant [ Time Frame: 6 months ]

    LV pacing success is defined as at least one LV pacing vector with:

    • Pacing Threshold (PT) ≤ 3.5V at 1ms pulse width, and
    • No phrenic nerve stimulation at PT+2V / 1ms pulse width.


Secondary Outcome Measures :
  1. Bizone LV pacing success rate at 6 months post implant [ Time Frame: 6 months ]

    Bizone LV pacing success is defined as two distant pacing vectors with:

    • A Pacing Threshold (PT) ≤ 3.5V at 1ms pulse width, and
    • No phrenic nerve stimulation at PT +2V / 1ms pulse width. Two pacing vectors are considered distant when cathode electrodes are separated by at least 30 mm.


Other Outcome Measures:
  1. Axone 4LV implantation success rate [ Time Frame: At implant, preferably within 15 days of enrollment ]
  2. Implantation duration [ Time Frame: At implant, preferably within 15 days of enrollment ]
  3. Fluoroscopy time [ Time Frame: At implant, preferably within 15 days of enrollment ]
    Fluoroscopy time is measured in minutes

  4. Fluoroscopy dose [ Time Frame: At implant, preferably within 15 days of enrollment ]
    Fluoroscopy dose is measured using dose area product (Gray.cm^2)

  5. Axone system handling assessment [ Time Frame: At implant, preferably within 15 days of enrollment ]
    Implanters will be asked to fill in a handling questionnaire and record observations related to the use of the Axone system.

  6. Axone implanters' learning curve [ Time Frame: At implant, preferably within 15 days of enrollment ]
    This endpoint will be based on fluoroscopy time for implantation. The effect of removing the 1st, 2nd, 3rd, etc implanted subjects on mean fluoroscopy time (per implanter and per site) will be calculated.

  7. Number of excitable myocardium areas at implant [ Time Frame: At implant, preferably within 15 days of enrollment ]
    "Excitable myocardium areas" are areas that can be paced by the implanted Axone 4LV lead.

  8. Effect of CRT therapy, in particular bizone pacing, on QRS parameters, at discharge and 6 months post implant [ Time Frame: At discharge, within 7 days of implant, and at 6 months ]
    The effect of monozone and bizone CRT pacing on duration of QRS is measured in milliseconds.

  9. Effect of CRT therapy, in particular bizone pacing, on Left Pre-Ejection Interval (LPEI), at discharge [ Time Frame: At discharge, within 7 days of implant ]
    LPEI (in milliseconds) is an electromechanical parameter that can be assessed using echocardiography.

  10. Axone 4LV lead pacing threshold [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]
    Pacing threshold is measured in Volts.

  11. Axone 4LV lead pacing impedance [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]
    Pacing impedance is measured in Ohms.

  12. Presence of phrenic nerve stimulation (PNS) with the Axone 4LV lead [ Time Frame: Implant (preferably within 15 days of enrollment), discharge (within 7 days of implant), 6 weeks, 3 months, 6 months ]
    The presence of PNS will be assessed at 10V using an external pacing system analyzer at implant, or at pacing threshold +2V at other visits.

  13. Axone 4LV lead programming [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]
    Lead programming will be reported using: (i) pacing amplitude (Volts), pulse width (milliseconds) and pacing vector(s) selected.

  14. Energy consumption associated with Axone 4LV lead [ Time Frame: 6 months ]
    Energy will be calculated using the formula: E=(pacing amplitude^2 x pulse width)/impedance. Energy, pacing amplitude, pulse width and impedance are measured in Joules, Volts, milliseconds, and Ohms, respectively.

  15. Axone system-related annual complication-free rate [ Time Frame: 12 months, 24 months 36 months, 48 months ]
    Definition of Axone system related complication is the same as for primary safety endpoint.

  16. Clinical response to CRT at 12 months post implant [ Time Frame: 12 months ]

    Clinical response will be determined by looking at functional improvement, reverse remodelling, freedom from heart failure events, and rate of non-responders:

    (i) functional improvement is defined as improvement in ≥1 NYHA (New York Heart Association) class from baseline to 12 months.

    (ii) reverse remodelling is a ≥12% increase in left ventricular end systolic volume index (LVESVi: LVESV [mL] and body surface area [m^2] will be combined to report LVESVi).

    (iii) freedom from heart failure events is defined as an absence of death or HF hospitalization.

    (iv) non-responders are all those who are not responders. A responder is defined as a subject that is not dead and who did not experience any HF hospitalization and that has a stable or improved NYHA class versus baseline.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indication for cardiac resynchronization therapy-defibrillator (CRT-D) device implant according to the latest ESC (European Society of Cardiology) guidelines
  • De-novo implant of a Platinium 4LV CRT-D device (or any newer 4LV CRT-D model manufactured by MicroPort CRM)
  • Reviewed, signed and dated informed consent form

Exclusion Criteria:

  • LV lead previous implant attempt
  • Upgrade to CRT from a previously implanted pacemaker or implantable cardioverter-defibrillator (ICD), or CRT device replacement
  • Known allergy to contrast media used for imaging during cardiac catheterization
  • Tricuspid valvular disease or any type of tricuspid replacement heart valve (mechanical or tissue)
  • Severe renal failure (creatinine clearance according to the Modification of Diet in Renal Disease (MDRD) formula < 30ml/min/m²)
  • Active myocarditis
  • Stroke, myocardial infarction or cardiac revascularization within 40 days prior to implant
  • Previous heart transplant or currently on heart transplant list
  • Life expectancy less than 1 year
  • Already included in another clinical study that could confound the results of this study
  • Pre-menopausal women
  • Less than 18 years old or under guardianship
  • Incapacitated subject, inability to understand the purpose of the study, or to meet follow-up visits at the implanting site as defined in the protocol
  • Diagnosis of drug addiction (substance use disorder)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04463641


Contacts
Layout table for location contacts
Contact: Anaïs Balland, MSc +33602000014 anais.balland@crm.microport.com

Sponsors and Collaborators
MicroPort CRM
Investigators
Layout table for investigator information
Principal Investigator: Frédéric Anselme, MD CHU de Rouen, France
Publications:

Layout table for additonal information
Responsible Party: MicroPort CRM
ClinicalTrials.gov Identifier: NCT04463641    
Other Study ID Numbers: LAXI01
First Posted: July 9, 2020    Key Record Dates
Last Update Posted: July 9, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MicroPort CRM:
Left Ventricular Lead
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases